Conversely, 88% (44/50) of patients with liver cancer and 54.4% (62/114) of patients with breast cancer have a similar tendency of under-expressed TNN. Additionally, KIR2DL1 was significantly over-expressed in kidney cancer (p ≈0) while significantly under-expressed in lung cancer (p ≈0). This evidence concerns the gene KIR2DL1 and breast carcinoma.